Please provide your email address to receive an email when new articles are posted on . Recombinant herpes zoster vaccine recipients had lower risk for developing dementia compared with those who ...

Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team ...

Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...

LYON, France--(BUSINESS WIRE)--BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission ...

Among older adults who received at least one dose of the recombinant shingles vaccine, vaccine effectiveness against any herpes zoster-related outcome was 56.1%. Getting a second dose yielded a ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the recombinant zoster vaccine experienced lower risks for mortality vs. the unvaccinated.

Evidence from a team of scientists at the University of Oxford indicates that the newer shingles vaccine is more protective against dementia compared to the previous shingles vaccine. Both shingles ...

The recombinant zoster vaccine (RZV) Shingrix demonstrated effectiveness in preventing herpes zoster (HZ) and postherpetic neuralgia among adults aged 50 years or older with rheumatoid arthritis (RA).

By Hugo Francisco de Souza New real-world evidence links shingles vaccination with reduced dementia risk, raising important questions about viral triggers, inflammation, and future prevention ...

Herpes zoster (HZ) is common in older people, with a lifetime risk of 25%. The main risk factors are advanced age and immunosuppression. People with a rheumatic and musculoskeletal disease have an ...

CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine ...